G57321FI
| Organisms | Evidence |
|---|---|
| Fasciola hepatica (liver fluke) | |
| Toxocara canis (dog roundworm) | |
| Echinococcus granulosus | |
| Oryctolagus cuniculus (rabbit) | |
| Ovis aries (sheep) |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
|---|---|---|---|---|
| ST6GALNAC2 | CMP-Neu5Ac |
|
para-nitrophenol | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
[alpha]-Bz | |
| ST6GALNAC3 | CMP-Neu5Ac |
|
Ser/Thr | |
| ST6GALNAC2 | CMP-Neu5Ac |
|
Ser/Thr | |
| ST6GAL2 | CMP-Neu5Ac |
|
para-nitrophenol |
| Pathway Name | Organism |
|---|---|
| E.coli O101 | Escherichia coli |
| E.coli O103 | Escherichia coli |
| E.coli O107 | Escherichia coli |
| E.coli O112ab | Escherichia coli |
| E.coli O112ac | Escherichia coli |
| E.coli O116 | Escherichia coli |
| E.coli O117 | Escherichia coli |
| E.coli O125ab | Escherichia coli |
| E.coli O127 | Escherichia coli |
| E.coli O128ab-H27 | Escherichia coli |
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 32033212 | The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth | Elshenawy S | 2020 Feb 04 |
|
| 31821125 | Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis | Sutherland JE | 2020 Feb 01 |
|
| 33295623 | Contrasting the conformational effects of α-O-GalNAc and α-O-Man glycan protein modifications and their impact on the mucin-like region of alpha-dystroglycan | Borgert A | 2020 Dec 09 |
|
| 33275144 | High-resolution visualization and quantification of nucleic acid–based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS) | He C | 2020 Dec 04 |
|
| 32310329 | Comprehensive N- and O-glycosylation mapping of human coagulation factor V | Ma C | 2020 Aug |
|
| 32808038 | Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates | Brown CR | 2020 Aug 18 |
|
| 32599652 | Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects | Habtemariam BA | 2020 Aug 13 |
|
| 32297877 | Core 1 O-N-acetylgalactosamine (O-GalNAc) glycosylation in the human cell nucleus | Cejas RB | 2020 Aug 11 |
|
| 32592692 | Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug | Debacker AJ | 2020 Aug 05 |
|
| 32417172 | O-linked N-acetylgalactosamine modification is present on the tumor suppressor p53 | Xu Z | 2020 Aug |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025